MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 10,851,676 shares of the Company’s common stock. Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the Selling Stockholders in the Offering. The Offering is expected to close on June 7, 2021, subject to customary closing conditions.
In addition, Syneos Health entered into an agreement with the Selling Stockholders to repurchase an aggregate of 500,000 shares of common stock from such Selling Stockholders in a private transaction, concurrently with the closing of the Offering, at the price at which the shares of common stock are sold to the public in the Offering, less underwriting discounts and commissions. The closing of the share repurchase is contingent on, and expected to occur simultaneously with, the closing of the Offering, subject to the satisfaction of other customary conditions. The closing of the Offering is not contingent on the closing of the share repurchase.
BofA Securities is acting as the sole underwriter of the Offering.
An automatic shelf registration statement (including a prospectus) relating to the Offering was filed with the Securities and Exchange Commission (“SEC”) on November 27, 2018 and became effective upon filing. Before you invest, you should read the registration statement, prospectus and other documents Syneos Health has made available with the SEC for information about Syneos Health and the Offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus and accompanying prospectus supplement, when available, may be obtained from:
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 25,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
